Found: 3
Select item for more details and to access through your institution.
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate <sup>177</sup>Lu-Lilotomab Satetraxetan.
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 1, p. 48, doi. 10.2967/jnumed.116.173922
- By:
- Publication type:
- Article
Three-stage segmentation of lung region from CT images using deep neural networks.
- Published in:
- BMC Medical Imaging, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12880-021-00640-1
- By:
- Publication type:
- Article
Pre-dosing with lilotomab prior to therapy with <sup>177</sup>Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 7, p. 1233, doi. 10.1007/s00259-018-3964-9
- By:
- Publication type:
- Article